Ocean Biomedical, Inc. (OCEA): Nasdaq/NYSE listing notice — Ocean Biomedical faces Nasdaq delisting; CFO and director resign

Ocean Biomedical, Inc.

Nasdaq Board declined to review Listing Council decision; final delisting action triggered under Rule 5830 and SEC Rule 12d2-2.
Director Michael Petersen resigned effective August 31, 2025; no disagreement cited.
CFO Jolie Kahn resigned effective August 5, 2025; no disagreement cited.
Company continues to work on previously announced power and cryptocurrency strategies.

item 3.01 item 5.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.85

Ocean Biomedical, Inc. received a nasdaq delisting notice notice regarding other (rules 5820(e)(6), 5830).

Exchange: nasdaq
Notice: delisting notice
Rules: 5820(e)(6), 5830

Exact text from the filing

July 31, 2025, the Company was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review the May 15, 2025 decision of the Nasdaq Listing and Hearing Review Council (the “Listing Council”) in the Company’s appeal proceding. Accordingly, pursuant to Nasdaq Rule 5820(e)(6), the decision of the Listing Council represents Nasdaq’s final action in this matter. Nasdaq will follow the procedures contained in Nasdaq Rule 5830 and the Securities and Exchange Commission (“SEC”) Rule 12d2-2 to remove the Company’s securities from listing.

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ocean Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-022271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.